BLA Resubmitted for Ocriplasmin for Symptomatic Vitreomacular Adhesion

Share this article:

ThromboGenics announced that it has resubmitted a Biologics License Application (BLA) with the FDA for ocriplasmin intravitreal injection 2.5mg/mL for the treatment of symptomatic vitreomacular adhesion (VMA) including macular hole.

Ocriplasmin has successfully completed two Phase 3 clinical trials for the pharmacological treatment of symptomatic VMA. Ocriplasmin is in Phase 2 clinical development for additional vitreoretinal conditions.

Ocriplasmin (microplasmin) is a truncated form of the human serine protease plasmin that retains its enzymatic properties and is believed to primarily target the fibronectin, laminin, and type IV collagen fibers that adhere the vitreous to the retina.

For more information call (212) 201-0920 or visit www.thrombogenics.com.

Share this article:

Related Resources